5/2/2023 0 Comments Unfolder dlbcl trial![]() In a per-protocol analysis of 11 patients who were excluded from RICOVER-noRTh due to undergoing unplanned RT, multivariate analysis demonstrated HRs of 2.7 (95% CI, 1.3–5.9 P = 0.011), 4.4 (95% CI, 1.8–10.6 P = 0.001), and 4.3 (95% CI, 1.7–11.1 P = 0.002) for EFS, PFS, and OS in patients not receiving RT to bulky disease, respectively. Also, patients who did not receive RT demonstrated trends towards inferior PFS (HR, 1.8 95% CI, 1.0–3.3 P = 0.058) and OS (HR, 1.6 95% CI, 0.9–3.1 P = 0.127). In multivariate analysis of the ITT population, EFS of patients was worse without additive RT (HR, 2.1 95% CI, 1.3–3.5 P = 0.005). Overall, 164/166 RICOVER-noRTh patients were evaluable after a median observation time of 39 months. who compared cohorts of the phase III RICOVER-60 study: one cohort received R-CHOP 圆 plus rituximab x2 plus involved-field Radiotherapy (RT), and the other did not receive RT (RICOVER-noRTh prospective amendment to trial). The presentation began by discussing a paper by Held et al. This abstract presentation included the first interim analysis results of the phase III OPTIMAL>60 study ( NCT01478542) and was given by Michael Pfreundschuh, MD, from University Saarland Medical School, Saarbrücken, Germany. Two key oral abstracts were presented on Diffuse Large B-Cell Lymphoma (DLBCL). Advani, MD, from the Stanford Cancer Institute, Stanford, CA, USA. Pagel, MD, PhD, of the Swedish Cancer Institute, Seattle, WA, USA, and Ranjana H. At the 2017 American Society of Clinical Oncology ( ASCO) Annual Meeting, an oral abstract session took place that was jointly chaired by John M. ![]()
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |